Latest Biotechnology News

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

BPH Global Limited secured $325,000 in funding during the December quarter, progressing its Indonesian seaweed venture and renewing key R&D partnerships. The company ends the quarter with $226,000 cash on hand and plans a $1 million capital raise at an upcoming EGM.

Avenira Limited finalised a $4.5 million strategic investment from Hebang Biotechnology and progressed key development milestones at its Wonarah Phosphate Project, signalling a focused push towards near-term production and long-term growth.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Clean TeQ Water Limited reports a landmark $11 million contract for its PHOSPHIX® phosphate removal plant in Ireland, alongside successful project deliveries and lithium recovery breakthroughs, setting the stage for improved financial performance in 2025.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.